Department of Community Health, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Serdang, Malaysia.
University Institute of Public Health, Faculty of Allied Health Sciences, University of Lahore, Punjab, Lahore, Pakistan.
JMIR Mhealth Uhealth. 2024 Jun 19;12:e50248. doi: 10.2196/50248.
The high prevalence of uncontrolled hypertension in Pakistan is predominantly attributed to poor medication adherence. As more than 137 million people in Pakistan use cell phones, a suitable mobile health (mHealth) intervention can be an effective tool to overcome poor medication adherence.
We sought to determine whether a novel mHealth intervention is useful in enhancing antihypertensive therapy adherence and treatment outcomes among patients with hypertension in a low- to middle-income country.
A 6-month parallel, single-blinded, superiority randomized controlled trial recruited 439 patients with hypertension with poor adherence to antihypertensive therapy and access to smartphones. An innovative, multifaceted mHealth intervention (Multi-Aid-Package), based on the Health Belief Model and containing reminders (written, audio, visual), infographics, video clips, educational content, and 24/7 individual support, was developed for the intervention group; the control group received standard care. The primary outcome was self-reported medication adherence measured using the Self-Efficacy for Appropriate Medication Adherence Scale (SEAMS) and pill counting; the secondary outcome was systolic blood pressure (SBP) change. Both outcomes were evaluated at baseline and 6 months. Technology acceptance feedback was also assessed at the end of the study. A generalized estimating equation was used to control the covariates associated with the probability of affecting adherence to antihypertensive medication.
Of 439 participants, 423 (96.4%) completed the study. At 6 months post intervention, the median SEAMS score was statistically significantly higher in the intervention group compared to the controls (median 32, IQR 11 vs median 21, IQR 6; U=10,490, P<.001). Within the intervention group, there was an increase in the median SEAMS score by 12.5 points between baseline and 6 months (median 19.5, IQR 5 vs median 32, IQR 11; P<.001). Results of the pill-counting method showed an increase in adherent patients in the intervention group compared to the controls (83/220, 37.2% vs 2/219, 0.9%; P<.001), as well as within the intervention group (difference of n=83, 37.2% of patients, baseline vs 6 months; P<.001). There was a statistically significant difference in the SBP of 7 mmHg between the intervention and control groups (P<.001) at 6 months, a 4 mmHg reduction (P<.001) within the intervention group, and a 3 mmHg increase (P=.314) within the controls. Overall, the number of patients with uncontrolled hypertension decreased by 46 in the intervention group (baseline vs 6 months), but the control group remained unchanged. The variables groups (adjusted odds ratio [AOR] 1.714, 95% CI 2.387-3.825), time (AOR 1.837, 95% CI 1.625-2.754), and age (AOR 1.618, 95% CI 0.225-1.699) significantly contributed (P<.001) to medication adherence. Multi-Aid-Package received a 94.8% acceptability score.
The novel Multi-Aid-Package is an effective mHealth intervention for enhancing medication adherence and treatment outcomes among patients with hypertension in a low- to middle-income country.
ClinicalTrials.gov NCT04577157; https://clinicaltrials.gov/study/NCT04577157.
在巴基斯坦,高血压的患病率居高不下,主要归因于药物治疗的依从性差。由于巴基斯坦有超过 1.37 亿人使用手机,因此一种合适的移动医疗(mHealth)干预措施可能是克服药物治疗依从性差的有效工具。
我们旨在确定一种新的 mHealth 干预措施是否有助于提高中低收入国家高血压患者的降压治疗依从性和治疗效果。
一项为期 6 个月的平行、单盲、优效性随机对照试验招募了 439 名高血压且药物治疗依从性差、能使用智能手机的患者。一项基于健康信念模型的创新的、多方面的 mHealth 干预措施(Multi-Aid-Package),包含提醒(书面、音频、视觉)、信息图、视频剪辑、教育内容和 24/7 个人支持,为干预组开发;对照组接受标准护理。主要结局是使用适当药物依从性自我效能量表(SEAMS)和药片计数测量的自我报告药物依从性;次要结局是收缩压(SBP)变化。基线和 6 个月时均评估这两个结局。研究结束时还评估了技术接受度反馈。使用广义估计方程控制与影响降压药物治疗依从性的概率相关的协变量。
在 439 名参与者中,有 423 名(96.4%)完成了研究。在干预后 6 个月时,与对照组相比,干预组的 SEAMS 评分中位数显著更高(中位数 32,IQR 11 与中位数 21,IQR 6;U=10,490,P<.001)。在干预组内,SEAMS 评分中位数在基线和 6 个月之间增加了 12.5 分(中位数 19.5,IQR 5 与中位数 32,IQR 11;P<.001)。药片计数法的结果显示,与对照组相比,干预组的依从性患者增加(83/220,37.2%与 2/219,0.9%;P<.001),且在干预组内也有所增加(差异 n=83,37.2%的患者,基线与 6 个月;P<.001)。在 6 个月时,干预组和对照组之间的 SBP 存在统计学显著差异(P<.001),干预组 SBP 降低 7mmHg(P<.001),对照组 SBP 升高 3mmHg(P=.314)。总体而言,干预组的未控制高血压患者人数减少了 46 人(基线与 6 个月),但对照组没有变化。分组(调整后的优势比[AOR]1.714,95%CI 2.387-3.825)、时间(AOR 1.837,95%CI 1.625-2.754)和年龄(AOR 1.618,95%CI 0.225-1.699)对药物依从性有显著影响(P<.001)。Multi-Aid-Package 获得了 94.8%的可接受性评分。
新型 Multi-Aid-Package 是一种有效的 mHealth 干预措施,可提高中低收入国家高血压患者的药物治疗依从性和治疗效果。
ClinicalTrials.gov NCT04577157;https://clinicaltrials.gov/study/NCT04577157。